Connect your AI

Alumis Inc. ALMS Total Liabilities

Total Liabilities at other companies

Bristol-Myers SquibbBMY

$66.37B-11.5%

Oruka Therapeutics, Inc.ORKA

$17.76M+43.4%

ANI PharmaceuticalsANIP

$859.67M+1.3%

Celldex TherapeuticsCLDX

$55.03M+50.8%

ImmunomeIMNM

$31.11M-12.5%

AmgenAMGN

——

Other financials

Income statement

Revenue$1.7M-90.0%

Operating income-$98.4M+3.1%

Net income-$93.1M+6.0%

EPS (diluted)-$0.74+59.3%

Balance sheet

Cash & equivalents$63.9M-50.3%

Total debt$35.7M+1,881%

Total equity$567.0M+237%

Total assets$671.6M+157%

Cash flow

Operating cash flow-$87.1M-8.4%

CapEx$164.0K+343%

Free cash flow-$87.2M-8.5%

Valuation

Market cap$3.12B+739%

Enterprise value$3.1B+1,238%

P/S371.9×—

Profitability

Operating margin-5,364%—

Net margin-2,825.7%—

FCF margin-4,487.4%—

Returns & leverage

Return on equity-64.6%—

Debt / equity0.1×+0.1×

Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Alumis Inc.'s total liabilities?: Alumis Inc. (ALMS) reported total liabilities of $104.57M in Q1 2026.
How has Alumis Inc.'s total liabilities changed year-over-year?: Alumis Inc.'s total liabilities increased by 12.5% year-over-year, from $92.98M to $104.57M.
What is the long-term trend for Alumis Inc.'s total liabilities?: Over 2 years (2023 to 2025), Alumis Inc.'s total liabilities has grown at a 43.8% compound annual growth rate (CAGR), from $53.5M to $110.64M.
What does total liabilities mean?: The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.